At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Retrospective Evaluation of the Effectiveness of Fixed-dose Combination Inhaled Corticosteroid /. Long-acting Beta Agonist (ICS/LABA) Therapy in the Management of Asthma in a Representative UK Primary Care Population
In Brief
An observational study evaluating Fluticasone / formoterol metered dose inhaler, Fluticasone / salmeterol dry powder inhaler, and 3 other interventions for Asthma. Completed, enrolled 815,377 participants across 1 site.
Detailed Summary
This study will evaluate and compare the effectiveness of asthma management in patients with evidence of persistent asthma following a switch in asthma therapy to combination inhaled glucocorticosteroid (ICS) / long-acting bronchodilator (LABA) therapy as either: fixed-combination fluticasone propionate / salmeterol (FP/SAL; Seretide®) via pressurised metered-dose inhaler (pMDI) or dry-powder inhaler (DPI) plus as-needed (prn) reliever therapy (salbutamol as DPI, BAI or pMDI), or fixed-combination budesonide / formoterol (BUD/FOR; Symbicort®) via DPI plus prn reliever therapy (salbutamol as DPI, BAI or pMDI or bricanyl as DPI). The final analysis plan will define exact comparators and age groups to be studied after reviewing baseline data.
Study Details
Timeline
Interventions
Prescribed at the same BDP-equivalent dose as baseline ICS
Prescribed at the same BDP-equivalent dose as baseline ICS
Prescribed at the same BDP-equivalent dose as baseline ICS
Prescribed at ≥twice BDP-equivalent dose as baseline ICS
Prescribed at ≥twice BDP-equivalent dose as baseline ICS
Prescribed at ≥twice BDP-equivalent dose as baseline ICS